otelixizumab
Diabetes trial disappointment for GSK and Tolerx
March 14, 2011Research and Development DEFEND-1, DEFEND-2, GSK, GlaxoSmithKline, Tolerx, diabetes, otelixizumab, type I diabetes
GSK and Tolerx’s type I diabetes drug otelixizumab has failed to meet its primary endpoint in a late-stage trial. Anti-CD3 …
